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We have previously reported a group of patients with congenital onset weakness associated with a deﬁciency of members of the syntro-
phin-a-dystrobrevin subcomplex and have demonstrated that loss of syntrophin and dystrobrevin from the sarcolemma of skeletal mus-
cle can also be associated with denervation. Here, we have further studied four individuals from a consanguineous Egyptian family with
a lethal congenital myopathy inherited in an autosomal-recessive fashion and characterized by a secondary loss of b2-syntrophin and
a-dystrobrevin from the muscle sarcolemma, central nervous system involvement, and fetal akinesia. We performed homozygosity
mapping and candidate gene analysis and identiﬁed a mutation that segregates with disease within CNTN1, the gene encoding for
the neural immunoglobulin family adhesion molecule, contactin-1. Contactin-1 transcripts were markedly decreased on gene-expres-
sion arrays of muscle from affected family members compared to controls. We demonstrate that contactin-1 is expressed at the neuro-
muscular junction (NMJ) in mice and man in addition to the previously documented expression in the central and peripheral nervous
system. In patients with secondary dystroglycanopathies, we show that contactin-1 is abnormally localized to the sarcolemma instead of
exclusively at the NMJ. The cntn1 null mouse presents with ataxia, progressive muscle weakness, and postnatal lethality, similar to the
affected members in this family. We propose that loss of contactin-1 from the NMJ impairs communication or adhesion between nerve
and muscle resulting in the severe myopathic phenotype. This disorder is part of the continuum in the clinical spectrum of congenital
myopathies and congenital myasthenic syndromes.Introduction
The dystrophin-associated protein complex (DAPC) is
a large, tightly associated oligomeric complex of proteins
located within the skeletal muscle membrane.1 The
DAPC is thought to connect the extracellular matrix to
the intracellular cytoskeleton and stabilize the plasma
membrane against stresses imposed during muscle con-
traction or stretch (reviewed in Ervasti and Sonnemann2).
Mutations in several members of the DAPC result in
human muscle disease.3 Many members of the DAPC,
e.g., utrophin (MIM 128240), a-dystroglycan (MIM
128239), biglycan (MIM 301870), the syntrophins, and
dystrobrevins, are also highly expressed at the neuromus-
cular junction (NMJ). The syntrophins and dystrobrevins
form a cytoplasmic subcomplex within the DAPC, binding
directly to dystrophin (MIM 300377) and utrophin (MIM
128240). This subcomplex serves as a membrane scaffold,
targeting signaling proteins such as ion channels, kinases,
and nNOS (MIM 163731) to the sarcolemma. In normal
human muscle, syntrophins and a-dystrobrevin (MIM
601239) also localize to the NMJ. In addition, a1-syntro-714 The American Journal of Human Genetics 83, 714–724, Decembphin (MIM 601017) and a-dystrobrevin localize to the
sarcolemma of both fast and slow ﬁbers; b1-syntrophin
(MIM 600026) is located predominantly at the sarcolemma
of type 2 ﬁbers, whereas b2-syntrophin (MIM 600027) is
largely expressed at the sarcolemma of type 1 ﬁbers.4 In
mice,however,b2-syntrophin anda-dystrobrevin-1 expres-
sion are largely restricted to the NMJ.5,6
Previously, we have identiﬁed 16 patients with congeni-
tal onset muscle weakness andmyopathic features onmus-
cle biopsy (out of 162 patients with congenital onset
myopathy or dystrophy of unknown cause) with isolated
secondary deﬁciency of the syntrophin-a-dystrobrevin
subcomplex by immunohistochemistry.4 Primary muta-
tions in members of the syntrophin-dystrobrevin complex
were excluded in all patients. Although the functional con-
sequence of syntrophin and a-dystrobrevin loss is not
known in humans, several knockout mouse models that
lack syntrophins and dystrobrevins have been generated
to elucidate their roles in skeletal muscle and nerve. How-
ever, the loss of a1- and b2-syntrophin in mice does not
affect muscle structure or function, and they do not
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a-dystrobrevin exhibit a mild muscular dystrophy10,11 and
cardiomyopathy.12 Interestingly, loss of either a-dystrobre-
vin or a1-syntrophin also result in abnormalities in NMJ
structure including reduced number of junctional fold
openings to the synaptic cleft and reduced junctional
AChR levels,8–13 suggesting that the syntrophin-dystrobre-
vin subcomplex may have a role in synaptic maturation
and remodeling. Adding additional weight to this hypoth-
esis is the ﬁnding that the syntrophin-dystrobrevin sub-
complex is differentially regulated during fetal develop-
ment not only in mice but also in humans.14,15 Unlike
other members of the DAPC, the expression of members
of the syntrophin-dystrobrevin subcomplex is also altered
in response to innervation and denervation, implicating
a participation in nerve-muscle communication15.
On the basis of these observations, we hypothesized that
the underlying cause of muscle weakness in our patient co-
hort may be neuropathic rather than myopathic. In this
study, we used homozygosity mapping, gene-expression
array, and a candidate gene approach to identify the dis-
ease-causing gene, CNTN1 (MIM 600016), in the affected
family members from the large consanguineous Egyptian
family ﬁrst described in Jones et al.4 The CNTN1 gene
encodes for contactin-1, a neural adhesion molecule of
the immunoglobulin (Ig) superfamily. We show contac-
tin-1 expression at the NMJ in normal human and mouse
skeletal muscle, and its mislocalization to the sarcolemma
in patients with secondary dystroglycanopathy. To our
knowledge, this is the ﬁrst report implicating mutations
in contactin-1 as a cause of human disease. We suggest
that a spectrum exists including both severe lethal myopa-
thy associated with fetal akinesia and congenital myas-
thenic syndromes much like those seen in the synaptopa-
thies caused by mutation in proteins expressed at the NMJ,
such as in AChR subunits and rapsyn.16,17
Material and Methods
Patient Material
Patient material was obtained from four affected infants and nine
unaffected family members from a large consanguineous family of
Egyptian background that have been brieﬂy reported previously.4
Informed consent for tissue and DNA samples was obtained from
parents and other contributing family members. Skeletal-muscle
biopsy samples were obtained from the four affected infants
for immunohistochemical and immunoblot analysis as well as
genomic DNA isolation and cDNA synthesis. Blood lymphocytes
(n ¼ 8) and buccal swab (n ¼ 1) was obtained for total DNA isola-
tion from unaffected family members. The study protocol was
approved by the ethics committees of The Children’s Hospital at
Westmead, Sydney, Australia.
Linkage Analysis
Genotyping was performed at the Australian Genome Research
Facility (AGRF), Melbourne, with the 5 cM ABI PRISM Linkage
Mapping Set version 2.5 marker set. An additional 15 microsatel-
lite markers were genotyped for ﬁne mapping in all individuals
and an additional three individuals. The genotyping was cleanedThe Americanof Mendelian and double-recombinant errors with MERLIN.18
Error rates were low, indicating that the pedigree was correct. We
carried out multipoint homozygosity mapping assuming a fully
penetrant recessive model with a rare allele frequency of 0.0001.
The initial genome-wide scan LOD score based on the eight family
members yielded a peak LOD of 2.9 at 12q. Analysis with the
additional ﬁne-mapping marker data and reﬁnement of genetic
maps increased evidence for linkage to highly signiﬁcant (LOD ¼
3.99) and narrowed the linkage region to 14cM at 12p12.1-q12.
Because the pedigree was too large (31 bits), the ﬁnal multi-
point mapping was carried out by dropping individuals from
the analysis until the pedigree was analyzable with exact multi-
point methods. Haplotype results were combined to delineate
the critical region.
DNA Isolation and Mutation Analysis
Total DNA extraction from blood lymphocytes (n ¼ 8) or cheek
swab (n ¼ 1) was performed with proteinase K or sodium dodecyl
sulfate (SDS) digestion. Genomic DNAwas isolated from 1 3 8 mm
cryosection of frozen skeletal muscle (n ¼ 4) with the GenomiPhi
DNA ampliﬁcation kit (Amersham Biosciences). We synthesized
cDNA by RT-PCR from mRNA extracted from frozen muscle
(patient V:4) and used PCR primers designed to amplify the entire
cDNA in overlapping segments (primer sequences for additional
genes screened available upon request). We analyzed PCR frag-
ments by direct sequencing using ABI Prism (ABI100 Version
3.2). Sequences were compared with the published NCBI se-
quences. To conﬁrm sequence changes found in cDNA, we ampli-
ﬁed the corresponding exons from genomic DNA using genome-
speciﬁc primers. We based codon numbering of CNTN1 on the
reported amino acid sequence, using the ﬁrst methionine as an
initiation codon (NCBI accession numbers NM_001843.2 and
NM_175038). Control genomic DNA was screened by a PCR-
RFLP test utilizing a MnlI restriction site abolished by the CNTN1
871 dupT mutation (primers REgCNTN-1: 50-GGGCCAAAATGT
GACC-30, REgCNTN-2: 50-aagccctccatgtgattt-30). For all primers
used forCNTN1 ampliﬁcation, see Table S1 available online. Align-
ments of contactin sequences from a variety of vertebrate species
were performed with the alignment program MAFFT.
In Silico Analysis
We used the University of California Santa Cruz (UCSC) Genome
Browser (July 2003 freeze), the National Center for Biotechnology
Information (NCBI) Entrez GenomeMap Viewer, and the Ensembl
Human Genome Server to search for known genes, expressed
sequence tags, and putative genes in the 12p12.1-q12 region.
This region contained 174 known gene sequences; however, 91 se-
quences were multiple entries of the same gene because of alterna-
tive splicing and seven were annotation errors within the Browser
(i.e., had no Unigene identiﬁer) leaving 76 genes within our region.
We performed bioinformatic analysis of public gene-expression
databases to prioritize our candidate genes in this region to those
expressed in muscle and nerve tissue. We used expression data
from brain as a substitute for nerve because data is incomplete
for gene expression in nerve and the spinal cord. Because public
databases may contain high levels of inaccuracy, we used these
two independent data sets to allow crossvalidation of results, Gen-
eCards’ electronic Northern (eNorthern), and NCBI SAGEmap
(Serial Analysis of Gene Expression). Of the 76 known genes in
our candidate region, 34 are expressed in muscle, and 44 areJournal of Human Genetics 83, 714–724, December 12, 2008 715
expressed in the brain. Except for one gene (CFTR/MRP), all mus-
cle genes are also expressed in the brain.
Expression-Array Analysis of Patients and Control
Skeletal Muscle
Total RNA was isolated from postmortem muscle biopsies taken
from three patients (V:2, V:3, and V:4) and six normal controls
of similar age-matched controls. RNA was extracted with Trizol re-
agent (Invitrogen) in accordance with the manufacturer’s instruc-
tions and then further puriﬁed with a QIAGEN RNeasy kit. The
concentration of total RNA was measured by absorbance at
260 nm and RNA quality was assessed on an Agilent bioanalyzer
2100. RNA target labeling, hybridization to Affymetrix Human
Genome U133 plus 2.0 arrays, and chip scanning were performed
by the Center for Array Technologies at the University ofWashing-
ton with standard Affymetrix protocols and an Affymetrix 3000
scanner. Data from the raw chip scans were uploaded to the Gen-
esifter (Vizix Labs) server and normalized by mean intensity, and
comparisons between the control and patient population were
performed with two sample t tests with a p value of 0.05. Genes
mapping to the region of chromosome 12 that contained the
mutation were analyzed for signiﬁcant changes.
Immunohistochemistry and Immunoblotting
Muscle biopsy samples were available from all four infants and
showed the muscle to be structurally normal with no signs of dys-
trophy. Biopsies were snap frozen in liquid-nitrogen-cooled iso-
pentane and stored in liquid nitrogen until required. Indirect
immunoﬂuorescence was performed on 8-mm-thick cryosections
with antibodies against all members of the DAPC especially those
associated with congenital muscular dystrophy (dystrophin, [a-,
b-, d-, and g-] sarcoglycans, laminin a2, b-spectrin, and a-dystro-
glycan) according to standard procedures.4 All antibodies were ob-
tained from Novacastra Laboratories (Newcastle upon Tyne, UK)
unless otherwise stated. Antibodies raised against a1-syntrophin
(SYN17), b1-syntrophin (SYN35), b2-syntrophin (SYN28)5,19 and
a-dystrobrevin-1 (DB670) and 2 (DB2)6 were provided by S.C
Froehner. A rabbit polyclonal antibody raised against sarcospan
was generously provided by Dr. Louis Kunkel (Boston,MA). Mono-
clonal anti-laminin a2 (MAB1922) was obtained from Chemicon,
and clone 4H8-2 was obtained from Alexis. Antibodies to the cyto-
plasmic domain of the a7-integrin chain [A2(346) and B2(347)]
were kindly provided by S.J. Kaufman and used as previously
described.20,21 a-Bungarotoxin, Alexa Fluor 488 conjugate was
obtained from Molecular Probes, and polyclonal contactin-1 anti-
body (AF904) was obtained from R&D Systems. For a-dystroglycan
(using clone VIA4-1 from Upstate Biotechnology), we treated the
muscle with ice-cold acetic acid:ethanol (1:1) for 1 min. For immu-
nodetection of a-dystrobrevin (DB670 and DB26), cryosections
were ﬁxed with 3% paraformaldehyde at room temperature for
10 min and then rinsed in PBS. Sections were blocked in 2% BSA
(bovine serum albumin) in PBS (phosphate-buffered saline) at
room temperature for 15 min. Sections were incubated in primary
antibody (diluted in 2% BSA) at room temperature for 2 hr or 4C
overnight and then were washed three times in PBS. Anti-mouse
CY3-conjugated, anti-mouse Alexa-488-conjugated, anti-goat
CY3-conjugated, and anti-rabbit CY3-conjugated secondary anti-
bodies (Jackson Immunoresearch Laboratories) were applied, and
sections were incubated at room temperature for 1 hr. After an
additional three washes in PBS, coverslips were applied over
Immumount. Images were captured with a Leica SP2 scanning716 The American Journal of Human Genetics 83, 714–724, Decemconfocal microscope. Immunoblot analysis was performed as de-
scribed previously.22 We performed all immunohistochemical
staining and immunoblot studies where possible using age-
matched muscle biopsies with normal histology as controls.
Results
As part of our initial cohort,4 we ascertained four patients
who belonged to a large consanguineous family of Egyp-
tian descent (Figure 1A). Individuals V:2, V:3, V:4, and
V:7 had a similar clinical presentation. Reduced fetal move-
ments were detected on ultrasound during the second and
third trimester. All infants were born between 28 and 35
weeks’ gestation and pregnancy was complicated by multi-
ple problems including polyhydramnios and growth retar-
dation. Three of the children showed no spontaneous
movements and died shortly after birth. One infant (V:7)
survived to 1 month of age but required intubation and
ventilation from birth. She remained ventilator dependent
because of poor respiratory effort. However, there was no
evidence of primary lung pathology requiring increased
ventilatory settings. Infant V:7 had low birth weight and
was noted to be hypotonic at birth with absent deep ten-
don reﬂexes, no suck or swallow, an absent Moro reﬂex,
and paucity or absence of spontaneous movement. She
had dysmorphic features including scaphocephaly, an
oval face, hypertelorism, and a high arched palate. She
was unresponsive to external stimuli. Her hands were
small with simian creases, arachnodactyly with overlap-
ping ﬁngers, and marked camptodactyly. She had ﬂexion
contractures in most joints but most notably the elbows
and hips. Echocardiogram and head ultrasound were nor-
mal. Muscle mass was generally reduced and all serum
levels were normal, including creatine kinase levels
(70 U/l; normal 0–230 U/l). She died 1 month after birth
(equivalent of 36 weeks’ gestation developmentally) from
respiratory failure precipitated by aspiration. An autopsy
conﬁrmed that the grossmorphology of all organs was nor-
mal including the central nervous system. Light micros-
copy of her skeletal muscle showed a minor variation in
ﬁber size (7–15 microns) and a mild increase in collagen
ﬁbrils between muscle ﬁbers. Electronmicroscopy revealed
a moderate number of foci in which small numbers of con-
tiguous sarcomeres were disrupted with disorganization of
the Z-band (Figures 1B and 1B0) and a reduced number of
mitochondria. The myoﬁlaments were also somewhat dis-
ordered within these foci, reminiscent of minicores. The
nerve biopsy was histologically normal. Based on the clin-
ical presentation and histological ﬁndings in muscle, the
diagnosis in this family was concluded to be a severe con-
genital myopathy.
The muscle biopsies from all four infants (V:2, V:3, V:4,
and V:7) were stained with antibodies to dystrophin, a-,
b-, g-, and d-sarcoglycan, sarcospan, a-dystroglycan, lami-
nin a2, b-dystroglycan, and collagen VI. All showed nor-
mal expression and localization at the muscle membraneber 12, 2008
The America(Figure 1C and data not shown). Integrin a7 staining was
absent; however, sequencing of the ITGA7 (MIM 600536)
gene identiﬁed no mutations within its coding region.23
Integrin a7 deﬁciency is now commonly recognized as
a secondary phenomenon in inherited myopathies.23,24
We stained the muscle with antibodies to members of
the syntrophin-a-dystrobrevin subcomplex and found
consistent abnormalities in all four patients. In patients
and age-matched controls, both a1-syntrophin and
b1-syntrophin localized to the muscle membrane (Figures
1D and 1E). Developmentally, b1-syntrophin is expressed
at the sarcolemmal membrane of all ﬁber types15 as is
observed in Figures 1E and 1E0 (age-matched control).
However, in all four patients, both b2-syntrophin and
a-dystrobrevin were absent from the muscle membrane
(Figures 1F and 1G). Immunohistochemistry with an anti-
body raised against slow myosin heavy chain (Figure 1H)
shows the presence of slow ﬁbers (which would normally
express b2-syntrophin) in the patient biopsy. Interestingly,
a-dystrobrevin-1 and -2 were retained at the NMJ even
though these molecules were lost from the sarcolemmal
membrane (Figure 1F). We performed immunoblot analy-
sis of b2-syntrophin on the skeletal muscle biopsy from
patient V:4 compared to age-matched control. A diffuse
band of ~59 kDa (the expected size for b2-syntrophin)
was detected in normal control muscle but not in the
patients’ muscle (data not shown). Antibodies raised
against a-dystrobrevin do not work reliably on immuno-
blotting to allow study. We previously sequenced the cod-
ing regions of b2-syntrophin and a-dystrobrevin as well as
a1-syntrophin in these patients and did not identify any
mutations.4
Figure 1. Family Pedigree and Skeletal Muscle Pathology
(A) Pedigree indicating family members studied with linkage anal-
ysis (initial mapping performed on individuals marked with an
asterisk) and genotype. Filled symbols indicate affected individ-
uals and half-filled symbols indicate carrier status (assessed by
genotyping). All empty symbols indicate family members for which
samples were unavailable for testing.
(B and B0) Electron micrograph of skeletal muscle from affected
individual V:7. Fibers contained foci of sarcomeric disruption and
z-line streaming. (B) shows a micrograph magnification at 45003,
and (B0) shows a micrograph magnification at 10,0003.
(C–H) Immunohistochemistry of muscle sections from patient V:7
(C, D, E, F, G, and H) and age-matched control (E0, F0, and G0) for
members of the dystrophin-associated protein complex. Shown
are (C) a-dystroglycan, (D) a1-syntrophin, (E and E0) b1-syntro-
phin, (F and F0) a-dystrobrevin-2, (G and G0) b2-syntrophin, and
(H) slow myosin. All members of the dystrophin-associated protein
complex were expressed normally except select members of the
syntrophin-a-dystrobrevin subcomplex. All affected family mem-
bers showed an absence of sarcolemmal membrane expression for
b2-syntrophin (which is normally expressed at the sarcolemma of
slow fibers (G0 marked with an asterisk in the age-matched control)
and a-dystrobrevin. Slow myosin shows the presence of slow fibers
in the patient biopsy. Scale bars represent 40 mm. Biopsies were
taken from quadriceps at developmental age 35 weeks’ gestation.n Journal of Human Genetics 83, 714–724, December 12, 2008 717
We thus carried out multipoint homozygosity mapping
on eight family members (including three of the four af-
fected individuals, Figure 1A) and identiﬁed a single, fully
informative region at 12p12.3-q13.11 of 25cM in which
only affected children were homozygous. The nonaffected
family members (unaffected carriers) were heterozygous
for this region. Further analysis with additional microsatel-
lite markers conﬁrmed coinheritance of the haplotype
with disease status in all family members (n ¼ 13) and fur-
ther narrowed the region of homozygosity to 14cM
(ﬂanked bymarkers D12S1688 andD12S1663), with a para-
metric LOD score of 4 (Figure 2A). There were no other ob-
vious candidate loci. This region (12p12.1-q12) contains
76 known genes (retrieved from the UCSC Genome
Browser, NCBI Entrez Genome Map Viewer, and Ensembl
Figure2. LinkageandMutationAnalysis
(A) Parametric multipoint linkage analysis
results of the chromosome 12 disease locus
in this Egyptian family. An idiotype of chro-
mosome 12 reports the position of the
locus within the flanking recombination
markers D12S1688 and D12S1663. Electro-
pherograms show the mutation containing
region in control, unaffected parent and
affected infant. The duplication of a thy-
mine between position 871 and 872 is indi-
cated by an arrow. Both the control and the
affected normal protein sequences are
shown below the respective electrophero-
gram. A schematic of the contactin-1 pro-
tein shows the position of the amino acid
mutation, S291fsX296, in relation to the
full-length 1018 amino acid protein (gray
ovals represent Ig-like domains, black
boxes indicate FNIII domains, and the
C-terminal arrow indicates the GPI-anchor).
(B) The nucleotides and amino acids flank-
ing the insertion (gray shaded) are highly
conserved in different species (human
contactin-1 nucleotides 848–894, amino
acids 262–314). Orthologs in Homo sapiens,
Pongo troglodytes, Pongo pygmaeus, Mus
musculus, Rattus norvegicus, Bos taurus, Gal-
lus gallus, Xenopus laevis, andDanio rerio are
shown. Stars indicate conserved residues.
Human Genome Server); only some
genes had identiﬁed functions,
whereas others encode ‘‘hypotheti-
cal’’ proteins with yet-to-be-deter-
mined function. We constructed an
in silico genomic map of the region,
using public databases (GeneCards’
eNorthern and NCBI SAGEmap) and
prioritized genes for mutation screen-
ing on the basis of expression levels
(i.e., present in skeletal muscle and
brain) and putative function or known interactions. We
excluded a number of candidate genes by sequence analy-
sis (n ¼ 24; PEPP2, IAPP, LDHB, KCNJ8, ABCC9, KRAS2,
BHLHB3, SSPN, ITPR2, STK38L, OVCH1, IPO8, DDX11,
MGC50559, LOC196394, FLJ10652, DNM1L, YARS2,
SYT10, KIF21A, FGD4, BICD1, MGC24039, and C12orf14).
Concurrently, we performed gene-expression-array as-
says on skeletal muscle RNA (matched for age and ﬁber
type proportion) from three patients (V:2, V:3, and V:4)
and six control samples to compare the expression levels
of the 76 genes within the linkage region. Fourteen genes
within this region were identiﬁed as being differentially
expressed in patients versus controls. We had previously
excludedmutations in half of the genes identiﬁed, as being
differentially expression in patients versus controls718 The American Journal of Human Genetics 83, 714–724, December 12, 2008
(ABCC9, STK38L, DNM1L, DDX11, ITPR2, IAPP, and
MGC24039), by sequence analysis. Of the remainder, the
most striking alteration in expression was seen for
CNTN1 with a 7.9- and 16.7-fold decrease in expression
in patients compared to controls depending on the probe
set used (227202_at and 227209_at, respectively). In addi-
tion, analysis using Genesifter annotated contactin-1 as
‘‘present’’ for all six control samples but ‘‘absent’’ in all
three patient samples.
We sequenced the coding region of the contactin 1 gene
(CNTN1) and identiﬁed a homozygous thymidine duplica-
tion, c.871dupT, within exon 8 in all four affected infants
(Figure 2A). The thymidine duplication (c.871dupT) in
exon 8 is predicted to result in a reading frameshift intro-
ducing a premature stop codon (S291fsX296). The truncat-
ing mutation occurs within the third Ig domain, present
within both human contactin-1 transcripts25 and is likely
to be rapidly degraded by nonsense-mediated decay. The
mutation was heterozygous in the parents of affected indi-
viduals and cosegregated with disease in each family mem-
ber. The mutation was not present on 121 healthy controls
of mixed ethnicity (242 chromosomes) or 27 unrelated
myopathy patients (54 chromosomes). Multiple align-
ments of contactin-1 orthologs from vertebrates and inver-
tebrates demonstrated that both the nucleotide and amino
acid sequences surrounding this duplication mutation
(nucleotides 871 and 872 in human CNTN1 sequence
NM_001843) are highly conserved during evolution
(Figure 2B). We have also sequenced contactin-1 in the
other members of the patient cohort with secondary syn-
trophin-dystrobrevin deﬁciencies described in Jones
et al.4 but did not identify any disease-causing mutations.
This suggests that this clinical and immunohistochemical
phenotype is genetically heterogeneous, and we consider
other proteins that interact with the syntrophins, dystro-
brevins and now contactin-1 as potential disease candi-
dates for these patients.
Figure 3. Contactin-1 Localization at
the NMJ in Both Human and Mouse Skel-
etal Muscle
Confocal immunofluorescence in normal
human and mouse quadriceps muscle
showing overlap between contactin-1
(CNTN) and a-bungarotoxin (Txn) used to
highlight the acetylcholine receptors of
the NMJ. Arrows are used to indicate an
example of this staining.
Contactin-1 expression has not
been extensively studied in tissues
other than the peripheral and central
nervous systems. However, very low
levels of contactin-1 mRNA have pre-
viously been reported in human
skeletal muscle.26 The low levels of
contactin-1 expression in skeletal
muscle is supported by our gene-expression-array control
data, which in turn demonstrated a signiﬁcant reduction
in the contactin-1 RNA transcript in muscle from affected
patients. Contactin-1 protein expression levels in normal
human and mouse skeletal muscle were below detection
levels by immunoblot analysis, although a correctly sized
band could be detected inmouse cerebellum in which con-
tactin-1 is abundantly expressed (see Berglund et al.27 and
data not shown). Immunohistochemical studies revealed
that contactin-1 expression is restricted to the NMJ in
both mouse and human skeletal muscle (Figure 3, n ¼ 3
each). Because of sampling-site variability and lack of sufﬁ-
cient patient muscle, additional examination of NMJ mor-
phology could not be performed. However, immunohisto-
chemistry was performed on the quadriceps muscles from
the cntn1 null27 and wild-type littermate mice for the syn-
trophins-dystrobrevin subcomplex. In contrast to loss of
b2-syntrophin and a-dystrobrevin from the sarcolemma
in human muscle lacking contactin-1, no difference in
staining was detected at the sarcolemmal membrane for
any members of this subcomplex in wild-type or cntn1
null mice (data not shown). Junctional staining was also
normal for these proteins. Speciﬁcally, b2-syntrophin
staining was restricted to the NMJ in both wild-type and
cntn1 null mice, and no difference was detected in either
the junctional or sarcolemmal staining of the different
a-dystrobrevin isoforms (data not shown).
The role of contactin-1 at the neuromuscular junction is
unknown. In Drosophila follicle cells, contactin forms
a complex with neurexin IV and neuroglian, which are
necessary for septate-junction formation and localiza-
tion.28 In the absence of a-dystroglycan, both neurexin
and contactin are promiscuously mislocalized, whereas
neuroglian expression is unaltered by loss of a-dystrogly-
can29. On this basis, we used immunochemistry to deter-
mine whether this relationship between contactin and
a-dystroglycan is maintained in human skeletal muscle.The American Journal of Human Genetics 83, 714–724, December 12, 2008 719
Figure 4. Contactin-1 Is Mislocalized
to the Sarcolemmal Membrane in the
Absence of Glycosylated a-Dystroglycan
Confocal immunofluorescence of skeletal
muscle biopsies from secondary a-dystro-
glycanopathy patients (mutations in FKRP
[B and C] and POMTGnT1 [D]), (E) denerva-
tion disorder (SMA [MIM 253300]), and (F)
Duchenne muscular dystrophy (DMD) as
compared to (A) control muscle with poly-
clonal anti-contactin-1 antibodies. Con-
tactin-1 expression is mislocalized to the
sarcolemmal membrane in response to
loss of glycosylated a-dystroglycan (indi-
cated with arrows in [B], [C], and [D])
but not in response to generalized dystro-
phic changes or denervation. In the con-
trol (A), contactin-1 is retained at the
NMJ (indicated with arrow). The control
shown is not age matched for all biopsies
because NMJs are not present in all human
biopsies as a result of sampling.In control skeletal muscle, contactin-1 expression was
restricted to the NMJ (Figures 3 and 4A). However, in
patients with secondary dystroglycanopathies (due to
mutations in the putative glycosyl transferases FKRP
[MIM 606612], Fukutin [MIM 253800], and POMTGnT
[MIM 606822]; n ¼ 6), contactin-1 was not restricted to
the NMJ but was also found on the sarcolemmal mem-
brane (Figures 4B–4D). Sarcolemmal expression of contac-
tin-1 was not observed in either denervated (n ¼ 4) or dys-
trophinopathy (MIM 310200, n ¼ 4) muscle (Figures 4E
and 4F), suggesting that the loss of glycosylated mem-
brane-bound a-dystroglycan is associated with the contac-
tin-1 mistargeting and is not secondary to the neuropathic
or dystrophic process. These data suggest that in humans,
as in Drosophila, the glycosylation state of a-dystroglycan
inﬂuences the localization of contactin-1.
Discussion
The congenital myopathies are a clinically and genetically
heterogeneous group of neuromuscular disorders that pres-
ent with hypotonia and areﬂexia, poor muscle bulk, and
generalized weakness and are usually deﬁned by a patho-
logical hallmark on muscle biopsy, e.g., nemaline bodies,
cores, and central nuclei. To date, the genes responsible
for inherited myopathies encode proteins with a variety
of structural and metabolic functions (reviewed in
North30) including components of the muscle contractile
machinery, proteins that mediate calcium release from
the sarcoplasmic reticulum, and proteins involved in
cytoskeleton reorganization and endocytosis. There is clin-
ical overlap between severe congenital myopathies and
congenital myasthenic syndromes due to mutations in
components of the NMJ such as acetylcholine receptor720 The American Journal of Human Genetics 83, 714–724, Decemsubunits and rapsyn.16,17 Both disorders can present with
fetal akinesia sequence, characterized by paucity of move-
ment in utero, and severe weakness and joint contractures
at birth. In this study, we report on a disease-causing muta-
tion in CNTN1—the gene encoding the glycosyl phospha-
tidylinositol (GPI)-anchored neural adhesion molecule
contactin-1—that results in a severe lethal congenital
myopathy with fetal akinesia and nonspeciﬁc myopathic
features on muscle biopsy.
In skeletal muscle, contactin-1 is primarily localized to
the NMJ. We propose that reduced expression of contac-
tin-1 at the NMJ causes a defect in neuromuscular trans-
mission, resulting in the severe myopathic phenotype.
We have previously demonstrated that denervation results
in secondary deﬁciency of members of the syntrophin-dys-
trobrevin complex,15 which is normally localized to the
NMJ. The loss of b2-syntrophin and a-dystrobrevin in
affected family members is probably secondary to the
defect in neuromuscular transmission or signaling. These
data further emphasize the overlap in the clinical spectrum
of congenital myopathies with fetal akinesia and congeni-
tal myasthenic syndromes and suggest that it is not only
the proteins necessary for neuromuscular signal transduc-
tion but also those related to NMJ adhesion that are impor-
tant for normal muscle development and growth.
Contactin-1 is a member of the immunoglobulin super-
family with a common structure of six C2 Ig-like domains,
four ﬁbronectin type III (FNIII) repeats, and a GPI anchor.25
Ig-like and FNIII domains are common building blocks of
many extracellular proteins involved in ligand recognition
and cell adhesion. They are also the main motifs of several
intracellular proteins associated with the contractile appa-
ratus of muscles such as titin, obscurin, and myotilin.
Contactin-1 expression has been extensively studied in
the mouse central nervous system and is thought to playber 12, 2008
a role in the establishment and stabilization of synaptic
connections.31,32 In the mouse central and peripheral ner-
vous systems, contactin-1 is associated with several signal-
ing molecules present in the extracellular matrix of neu-
rons and glia. Several lines of evidence suggest a critical
role for contactin-1 in the regulation of neurite growth,
synapse formation, fasciculation, and myelin organization
(reviewed in Falk et al.33).
Several different contactin-1 knockdown models have
been generated so that the in vivo functions of contac-
tin-1 could be determined. Knockdown of cntn1 expression
in Xenopus impairs neurogenesis and outgrowth of sensory
axons.34 Antibody perturbation induces misguidance of
central axons of proprioceptive dorsal root ganglion neu-
rons of chicks.35 Contactin-1 null mice are severely ataxic,
exhibit muscle weakness and growth retardation, and die
within the ﬁrst 18 days of life. The mice show defects in
the micro-organization of the cerebellar circuitry,27 disrup-
tion of paranodal junctions,36 and impaired synaptic plas-
ticity.37 In the affected infants in our study family, central
and peripheral nervous system involvement could not be
well documented because of their early death. The one
infant who survived for 1 month responded poorly to
external stimuli. Although thought to be a possible conse-
quence of birth asphyxia, this clinical phenotype may be
associated with contactin-1 mutations. Skeletal muscle
function and NMJ morphology and function have not
been studied in detail in our patient group or in the contac-
tin-1 null mouse; however, leg splaying was evident in
contactin-1 null mice, suggestive of muscle weakness and
reminiscent of the ‘‘frog-leg’’ posture adopted by patients
with congenital myopathy.
The mutation in CNTN1 described in this study intro-
duces a premature stop codon at position 296 within the
third Ig-like domain. Little is known about the contactin-
1 binding partners in skeletal muscle; however, this
domain is crucial for tenascin binding in the nervous
system38,39 and would be abolished with this mutation.
Tenascin-C (MIM 187380) has been predominantly stud-
ied within the central nervous system; however, one study
showed expression also at the neuromuscular andmyoten-
dinous junctions.40 Tenascin-C-deﬁcient mice exhibit
long-term impairment of skeletal muscle reinnervation,
suggesting that tenascin-C plays an important role in the
formation and stabilization of the NMJ.41 Contactin-1
also interacts with speciﬁc sodium channel isoforms in
the central and peripheral nervous system,42–46 but
whether this interaction occurs with the skeletal-muscle-
speciﬁc isoforms has yet to be investigated. The syntro-
phins also directly associate with voltage-gated sodium
channels in brain and skeletal muscle.47 In mice, muta-
tions in the neuronal voltage-gated sodium channel,
Nav1.6 (MIM 600702) cause an ataxic phenotype (i.e.,
med mouse; neurological mutant with ‘‘motor endplate
disease’’48) or muscular dystrophy (i.e., a spontaneous
mutation resulting in muscle degeneration; dmumouse49).
Both mouse models are characterized by early-onsetThe Americanprogressive paralysis of the hind limbs due to muscle atro-
phy during the second week of life and subsequent lethal-
ity in the ﬁrst month of life. Themedmouse also presented
with Purkinje cell degeneration, much like the cntn1-null-
mouse model.
Unlike the majority of DAPC members, the syntrophins
and dystrobrevins in skeletal muscle are regulated by neu-
ral signaling; their expression levels and localization are
altered by loss of innervation (as seen in human denerva-
tion disorders).15 Glycosylation of a-dystroglycan is regu-
lated in a similar manner.50 The potential interaction
between the syntrophin-dystrobrevin subcomplex and
a-dystroglycan within the DAPC and contactin-1 may con-
tribute to the central nervous system defects seen in both
patients with muscle disease and the knockout mouse
models (cntn1, med, and dmu). In several secondary a-dys-
troglycanopathies, loss or abnormal glycosylation of brain
dystroglycan can also result in CNS defects as well as de-
layed NMJ formation and a delay in muscle formation.51
Both the syntrophin (a1- and b2-) and dystrobrevin
(a- and b-) knockout mouse models are also reported to
exhibit subtle functional defects, such as performance in
sensorimotor tests, that cannot be explained by NMJ
abnormalities9,52.
The abnormalities in syntrophins and a-dystrobrevin in
patients with amutation in CNTN1 suggests an association
between contactin-1 and the syntrophin-dystrobrevin sub-
complex. Another member of the DAPC, biglycan regu-
lates the membrane expression of the syntrophin-dystro-
brevin complex in skeletal muscle. Biglycan null mice
show abnormal syntrophin-dystrobrevin expression, simi-
lar to our patient cohort;53 we have excluded primary
biglycan mutations in all of these patients.54 Biglycan
interacts directly with a-dystroglycan and, in Drosophila,
expression of a-dystroglycan at the sarcolemmal mem-
brane precludes incorrect membrane localization of con-
tactin.29 In this study, we show that contactin-1 is alsomis-
localized to the sarcolemmal membrane in humans with
secondary dystroglycanopathies. Dystroglycan is normally
expressed in the brain, and loss of dystroglycan in the
brain-speciﬁc dystroglycan knockout mouse results in
structural and functional brain abnormalities.55 Similarly,
in several secondary a-dystroglycanopathies, loss or abnor-
mal glycosylation of brain dystroglycan also results in CNS
defects, as well as abnormal NMJ formation and delayed
terminal muscle formation.51 In combination, these data
suggest that contactin-1 may also contribute to disease
pathogenesis in a wider spectrum of disease phenotypes
including the dystroglycanopathies. Although the precise
function of contactin-1 in skeletal muscle is unknown, it
is possible that its absence results in disruption of signaling
pathways through theDAPC andhas a deleterious effect on
musclemembrane function or integrity, accounting for the
muscle weakness observed in patients with CNTN1 muta-
tions. This hypothesis warrants further investigation.
In summary, we have identiﬁed a mutation within the
neural adhesion molecule, contactin-1 in patients withJournal of Human Genetics 83, 714–724, December 12, 2008 721
lethal congenital myopathy, characterized by the second-
ary loss of b2-syntrophin and a-dystrobrevin from the sar-
colemma and central nervous system involvement. To our
knowledge, this is the ﬁrst time contactin-1 has been
linked to human disease. In patient muscle biopsies, we
show that contactin-1 transcript levels are signiﬁcantly de-
creased compared to controls and demonstrate that con-
tactin-1 is localized to the NMJ. The NMJs in patients
with CNTN1 mutations may thus be compromised, be-
cause of the absence, mislocalization, or disruption in sig-
naling capabilities of various NMJ-associated proteins,
leading to muscle weakness. To our knowledge, our work
is the ﬁrst to link disruptions of contactin-1 to human dis-
ease and further emphasizes the overlap in the clinical
spectrum of congenital myopathies and congenital myas-
thenic syndromes.
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